Charles S. Fuchs
CIK: 0001719576
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Fuchs Charles S.
Fuchs Charles S. (SEC CIK 0001719576) files insider reports with the SEC as President, R&D of Erasca, Inc. (ERAS) and Director of CytomX Therapeutics, Inc. (CTMX).
Signal8 holds 4 ownership filings by Fuchs Charles S. (2 Form 3, 2 Form 4), filed between Jul 30, 2026 and Aug 12, 2026. Those filings report 2 transactions, from Jul 24, 2026 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fuchs Charles S.'s filings is in SAN DIEGO, CA.
Recent filings by Fuchs Charles S.
Other insiders filing for Erasca, Inc. (ERAS)
- Start Valerie Denise Harding, Director
- LIU JEAN I, Director
- Multani Pratik S, Director
- Casdin Alexander W., Director
- Hambleton Julie, Director
- Bristol James Arthur, Director